ClinicalTrials.govpublic full text
Efficacy and Safety of the Cryopreserved Formulation of OTL-101 in Subjects With ADA-SCID
severe combined immunodeficiency due to ada deficiency, gene therapy, hematopoietic and progenitor cells, lentiviral vector, ada-scid, interventional, phase1, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 860516
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.